Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Leukemia
Sun Yat-sen UniversitySmall moleculePhase 4 / ApprovedDormant
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 65/ 100
Competitive context
125 Active assets in the Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE Inhye Ahn | Phase 3 | BB |
MERCAPTOPURINE ANHYDROUS Dana-Farber Cancer Institute | Phase 3 | BB |
ASPARAGINASE Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 3 | BB |
FILGRASTIM Hospital General de Mexico | Phase 4 | BB |
Idarubicine Affiliated Hospital of Nantong University | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →